share_log

MedMira Reports Second Quarter Results FY2024

MedMira Reports Second Quarter Results FY2024

MedMira 公佈第二季度業績 FY2024
Accesswire ·  04/02 10:30

HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024.

新澤西州哈利法克斯/ACCESSWIRE/2024年4月1日/MedMira Inc.(MedMIRA)(多倫多證券交易所股票代碼:MIR)今天公佈了截至2024年1月31日的季度財務業績。

Corporate update

公司最新消息

During Q2 FY2024, MedMira received the US FDA 510(k) clearance for the HIV-2 claim on the Reveal G4 Rapid HIV-1/2 antibody test in the United States. This major milestone allows the Company to significantly grow its market share and revenue in the United States, while re-confirming its quality for its upcoming Clinical Laboratory Improvement Amendments (CLIA) waiver. The Reveal G4 Rapid HIV-1/2 is the fastest high quality rapid test which is now available in the United States and can be sold to CLIA laboratories, clinics and hospitals.

在 FY2024 第二季度,MedMira 在 Reveal 上的 HIV-2 索賠獲得了美國 FDA 510 (k) 的許可 在美國進行的 G4 快速 HIV-1/2 抗體測試。這一重要里程碑使公司能夠顯著增加其在美國的市場份額和收入,同時再次確認其即將到來的臨床實驗室改進修正案(CLIA)豁免的質量。揭秘 G4 Rapid HIV-1/2是最快的高質量快速檢測,現已在美國上市,可以出售給CLIA實驗室、診所和醫院。

Furthermore, in Q2 FY2024, the Company successfully completed additional studies to supports its current submission to Health Canada. These studies were in relation to maternal screening and in support to extend MedMira's intended use with its application.

此外,在 FY2024 第二季度,該公司成功完成了更多研究,以支持其目前向加拿大衛生部提交的文件。這些研究與孕產婦篩查有關,旨在通過應用擴大MedMira的預期用途。

In addition, MedMira expanded its Commercialisation Department by appointing a new Vice President of Business Development and Sales based in the United States. With this step, the Company is continuing its strategic plan to enhance its presence in North-America and grow its brand and revenue. A separate announcement will be issued on this matter.

此外,MedMira任命了駐美國的新業務開發和銷售副總裁,從而擴大了其商業化部門。通過這一舉措,公司將繼續其戰略計劃,以加強其在北美的影響力,增加其品牌和收入。將就此事單獨發佈公告。

Subsequent Events:

後續事件:

  • The Company submitted its supporting syphilis data to Health Canada for their final review. The Company's syphilis component showcased an outstanding performance and accurately identified all previously syphilis-infected cases, demonstrated reliability in confirming negatives, and presented potential for maternity screening. MedMira will provide an update as soon as a response is received.
  • The Company received the Canadian patent for its MiROQTM system and with it further expanded its IP portfolio.
  • MedMira has signed an additional distributor for the United States and a joint press release will be issue in due time.
  • 該公司將其支持梅毒數據提交給加拿大衛生部進行最終審查。該公司的梅毒成分表現出色,準確識別了所有先前感染梅毒的病例,在確認陰性方面表現出可靠性,並具有進行產婦篩查的潛力。收到回覆後,MedMira將立即提供最新信息。
  • 該公司獲得了 miRO 的加拿大專利QTM 系統,並進一步擴大了其知識產權組合。
  • MedMira已與美國的另一家分銷商簽約,並將在適當時候發佈聯合新聞稿。

Profit and Loss Highlights

損益亮點

  • Revenue: The Company recorded revenues in Q2 FY2024 of $148,695 compared to Q1 FY2024 $117,862 and $170,538 in the same period last year.
  • Gross Profit: The Company recorded a gross profit in Q2 FY2024 of $68,137 compared to $70,633 in Q1 FY2024 and $89,937 in the same period last year.
  • Operating expenses: The Company recorded for this quarter operating expenses of $579,374 compared to $668,729 in Q1 FY2024 and $459,746 in the same period last year.
  • Net (loss) income: The Company recorded a net loss of $590,789 compared to a loss of $490,508 for the same period last year.
  • 收入:該公司在 FY2024 第二季度的收入爲148,695美元,而第一季度 FY2024 的收入爲117,862美元,去年同期爲170,538美元。
  • 毛利:該公司在 FY2024 第二季度的毛利爲68,137美元,而第一季度 FY2024 的毛利爲70,633美元,去年同期爲89,937美元。
  • 運營支出:該公司本季度的運營支出爲579,374美元,而 FY2024 第一季度爲668,729美元,去年同期爲459,746美元。
  • 淨(虧損)收入:該公司的淨虧損爲590,789美元,而去年同期的虧損爲490,508美元。

Balance Sheet Highlights

資產負債表亮點

  • Assets: The Company recorded a decrease of its assets by $120,828 between Q1 FY2024 and Q2 FY2024 which was mainly due depreciation on fixed assets.
  • Liabilities: The Company's liabilities increased by $148,591 between Q1 FY2024 and Q2 FY2024. The Company's current liabilities increased by $445,828 was mainly due to increase in advances.
  • Loans in default decreased by $36,791 or 1% compared to last quarter. All other long and short terms debts are currently under negotiation to restructure terms and conditions of repayment.
  • Working Capital deficit: As a result of the changes noted above, the Company recorded a higher working capital deficit of $513,163 or 3% compared to last quarter.
  • 資產:在 FY2024 第一季度和 FY2024 第二季度之間,該公司的資產減少了120,828美元,這主要是由於固定資產的折舊。
  • 負債:在 FY2024 第一季度和 FY2024 第二季度之間,該公司的負債增加了148,591美元。該公司的流動負債增加了445,828美元,這主要是由於預付款的增加。
  • 與上一季度相比,違約貸款減少了36,791美元,下降了1%。所有其他長期和短期債務目前正在談判中,以調整還款條款和條件。
  • 營運資金赤字:由於上述變化,與上個季度相比,該公司的營運資金赤字增加了513,163美元,增長了3%。

The Company's financial statements and management's discussion and analysis are available on the Company's profile on SEDAR at . For matters of going concern, reference is made to the Auditor's Emphasis of Matter statement in the fiscal year ended 2023 Auditors Report and note 2b in the audited financial statements which are also available on SEDAR.

公司的財務報表以及管理層的討論和分析可在SEDAR上的公司簡介中查閱,網址爲 。對於持續經營的事項,請參閱截至2023財年的核數師報告中的審計員重點事項表和已審計財務報表中的附註2b,這些報表也可在SEDAR上查閱。

About MedMira

關於 MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

MedMira 是快速垂直流 (RVF) 技術的開發者和所有者。該公司基於RVF技術的快速測試應用程序僅需三個簡單步驟即可爲醫院、實驗室、診所和個人提供對HIV和丙型肝炎等疾病的即時診斷。該公司的測試在全球市場上以Reveal、Multipo和Miriad品牌出售。MedMira的公司辦公室和製造設施位於加拿大新斯科舍省的哈利法克斯,該公司在美國設有銷售和客戶服務辦公室。欲了解更多信息,請訪問 medmira.com。關注我們 推特領英

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

本新聞稿包含前瞻性陳述,這些陳述涉及風險和不確定性,反映了公司當前對未來事件的預期,包括有關可能批准和推出新產品、未來增長和新商機的陳述。實際事件可能與本文預測的事件存在重大差異,取決於許多因素,包括但不限於不斷變化的市場狀況、成功和及時地完成臨床研究、與監管批准程序相關的不確定性、公司聯盟的建立以及公司季度文件中不時詳述的其他風險。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

MedMira Contacts:

MedMira 聯繫人:

Markus Meile, CFO
Tel: 902-450-1588
Email: ir@medmira.com

Markus Meile,首席財務官
電話:902-450-1588
電子郵件:ir@medmira.com

SOURCE: MedMira

資料來源:MedMira


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論